Premium
Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience
Author(s) -
Sher Linda,
Jennings Linda,
Rudich Steven,
Alexopoulos Sophoclis P.,
Netto George,
Teperman Lewis,
Kinkhabwala Milan,
Brown Robert S.,
Pomfret Elizabeth,
Klintmalm Goran
Publication year - 2011
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/j.1399-0012.2011.01561.x
Subject(s) - medicine , immunosuppression , hepatitis c virus , liver transplantation , prospective cohort study , hepatitis c , gastroenterology , transplantation , surgery , randomized controlled trial , liver disease , virus , immunology
Sher L, Jennings L, Rudich S, Alexopoulos SP, Netto G, Teperman L, Kinkhabwala M, Brown RS Jr, Pomfret E, Klintmalm G; HCV‐3 Study Group. Results of live donor liver transplantation in patients with hepatitic C virus infection: the HCV 3 trial experience.
Clin Transplant 2011 DOI: 10.1111/j.1399‐0012.2011.01561.x.
© 2011 John Wiley & Sons A/S. Abstract: Chronic hepatitis C virus (HCV) is the most common disease indication for liver transplantation (LT). Outcomes are compromised by near universal recurrence of HCV. A prospective multi‐center randomized study to evaluate immunosuppressive strategies in HCV+ transplant recipients provided the opportunity to assess impact of live donor (LD) LT. Two hundred and ninety‐five patients undergoing LT for HCV (260 deceased donor [DD] recipients/35 LD recipients), randomized to three regimens, were followed for two yr for patient and graft survival and rate and severity of recurrent HCV. Biopsies were performed at baseline, 3, 12, and 24 months. One‐ and two‐yr patient survival for LD recipients was 88.1% and 81.1% vs. 90.5% and 84.6% for DD recipients (p = 0.5665). One‐ and two‐yr graft survival for LD recipients was 82.9% and 76.2% vs. 87.9% and 81.7% for DD recipients (p = 0.3921). Recurrent HCV did not account for more deaths or graft losses in the LD recipients. In this prospective study, controlled for immunosuppression, use of LD organs did not increase the rate or severity of HCV recurrence. The more elective nature of LDLT affords an opportunity to manipulate donor and recipient factors that can impact upon outcomes.